ScreenerHero

DMP Dermapharm Holding SE

XETRA · DE · Healthcare · Drug Manufacturers - Specialty & Generic · ir.dermapharm.de
37.45EUR-0.13%Mkt Cap: 2.02B $P/E: 13.52

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland,…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD

Key Statistics

Company
Market Cap2.02B USD
Enterprise Value3.07B USD
Revenue (TTM)1.29B USD
Gross Profit851.01M USD
Net Income (TTM)143.93M USD
Revenue/Share22.36 EUR
Last Price37.45 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3.6K
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINDE000A2GS5D8
Valuation
P/E (Trailing)13.52
P/E (Forward)12.64
PEG—
EV/EBITDA9.12
EV/Revenue2.39
P/S1.57
P/B3.45
EPS (TTM)2.77
EPS (Forward)2.97
52W Range
32.1527% of range51.90
52W High51.90 EUR
52W Low32.15 EUR
Profitability
Gross Margin67.21%
Oper. Margin15.86%
EBITDA Margin26.19%
Profit Margin11.37%
ROE19.07%
ROA6.06%
Growth
Revenue Growth4.80%
Earnings Growth20.50%
Cash Flow & Leverage
Operating CF249.07M USD
CapEx (TTM)45.78M USD
FCF Margin13.08%
FCF Yield8.33%
Net Debt1.06B USD
Net Debt/EBITDA3.14
Balance Sheet
Debt/Equity1.52
Current Ratio1.71
Quick Ratio0.75
Book Value/Sh10.86 EUR
Cash/Share3.96 EUR
Dividends
Fwd Div Rate0.88 EUR
Trail. Div Rate0.88 EUR
Div. Yield2.35%
5Y Avg Yield2.40%
Payout Ratio31.77%
Ex-Div DateJun 29, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)51.00 EUR
Upside (mean)+36.2%
Target Range44.00 EUR – 60.00 EUR
44.00+36.2% to mean60.00
# Analysts4
Ownership
Shares Out.49.54M
Float6.46M
Insiders89.30%
Institutions7.28%
Technical
SMA 5039.67 (-5.6%)
SMA 20042.06 (-11.0%)
Beta0.85
S&P 52W Chg14.58%
Avg Vol (30d)44.54K
Avg Vol (10d)19.15K
Technical Indicators
RSI (14)36.9
MACD-0.4161
MACD Signal-0.3602
MACD Hist.-0.0559
BB Upper40.03 EUR
BB Middle38.64 EUR
BB Lower37.25 EUR
BB Width7.21%
ATR (14)0.8506 EUR
Vol Ratio (20d)0.60x